Last updated 10 days ago
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
901 patients around the world
Available in Chile, Argentina
Sanofi
2Research sites
901Patients around the world
This study is for people with
Dermatitis
Atopic dermatitis
Requirements for the patient
From 12 Years
All Gender
Medical requirements
StudyATLANTIS
SponsorSanofi
Conditions
Atopic dermatitis
Requirements
From 12 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05769777
